Mir-21 和 Mir-125b 作为突尼斯女性上皮性卵巢癌的治疗诊断生物标志物。

Mir-21 and Mir-125b as theranostic biomarkers for epithelial ovarian cancer in Tunisian women.

机构信息

Laboratory of Mycology, Pathologies and Biomarkers (LR16 ES05), Faculty of Sciences of Tunis, University Tunis El Manar, Tunis, Tunisia.

Department of Internal Medicine, Naef K. basile Cancer Institute American University of Beirut, Beirut, Lebanon.

出版信息

Afr Health Sci. 2023 Jun;23(2):256-264. doi: 10.4314/ahs.v23i2.29.

DOI:10.4314/ahs.v23i2.29

PMID:38223583

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10782357/

Abstract

BACKGROUND

Ovarian cancer (OC) is the third most common cancer in women and the leading cause of death associated with gynecologic tumors. Because this disease is asymptomatic in the early stages, most patients are not diagnosed until the late stages. This highlights the need for the development of diagnostic biomarkers. MicroRNAs (miRNAs), small non-coding RNAs, are currently being explored as potential biomarkers for the early detection of various malignancies in humans. However, their expression and diagnostic value in OC have not been well studied.

MATERIALS AND METHODS

the plasma levels of miR-21, miR-200a, miR-200b, miR-200c, miR-205 and miR-125b were determined in epithelial ovarian cancer (EOC) patients and healthy controls by Reverse Transcription Quantitative Realtime Polymerase Chain Reaction . The expression levels of the deregulated microRNAs were analysed according to clinical characteristics.

RESULTS

It was found that miR-21 and miR-125b were upregulated in EOC compared with healthy controls. Moreover, decreased miR-125b was associated with resistance to platinum-based chemotherapy.

CONCLUSIONS

Our data suggest that miR-21 and miR-125b in plasma may serve as potential circulating biomarkers for the early detection of EOC. MiR-125b may also be useful for predicting chemosensitivity in EOC patients.

摘要

背景

卵巢癌（OC）是女性中第三常见的癌症，也是妇科肿瘤相关死亡的主要原因。由于这种疾病在早期无症状，大多数患者直到晚期才被诊断出来。这凸显了开发诊断生物标志物的必要性。MicroRNAs（miRNAs）是小的非编码 RNA，目前正在被探索作为人类各种恶性肿瘤早期检测的潜在生物标志物。然而，它们在 OC 中的表达和诊断价值尚未得到充分研究。

材料和方法

通过逆转录定量实时聚合酶链反应（Reverse Transcription Quantitative Realtime Polymerase Chain Reaction），在卵巢上皮癌（EOC）患者和健康对照者的血浆中测定 miR-21、miR-200a、miR-200b、miR-200c、miR-205 和 miR-125b 的水平。根据临床特征分析失调 microRNAs 的表达水平。